This protocol covers the structured management of malignant neoplasm of the commissure of lip in patients with lip cancer at T1 or T2 stage — an early-stage presentation where tumour size and extent remain limited.
The patient presents with lip cancer staged at T1 or T2. At these early stages, five-year crude survival rates for surgical treatment are approximately 75–80 per cent, compared with 40–50 per cent for T3 and T4 tumours. Early stage lip cancer can be addressed by more than one treatment modality, and this protocol specifically targets the approach when recurrent disease must be managed.
The approach for recurrent lip cancer at this stage centres on a surgical intervention — the complete protocol details the full indication criteria, sequencing, and decision points that guide its use.
DOI: 10.1017/S0022215116000499
The five-year crude survival rates for surgical treatment are about 75–80 per cent for T1 to T2 tumours, dropping to 40–50 per cent for T3 and T4 tumours.
Early stage cancer can be treated equally well by surgery or radiation therapy.
Even re-excision because of local failure leads to salvage in 75–80 per cent of cases.